Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Zacks News
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
A strong international presence and strategic buyouts aid Varian Medical (VAR); margins pressed.
Quest Diagnostics Rides on Product Launches, Strategic Deals
by Zacks Equity Research
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed's (CHE) subsidiaries continue to register strong sales.
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
by Zacks Equity Research
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
Genomic Health (GHDX), BioCartis Extend Deal to Urology
by Zacks Equity Research
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
by Zacks Equity Research
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance
by Zacks Equity Research
Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) continues to witness strong conversion wins for new XT series.
CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing
by Zacks Equity Research
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
QIAGEN's New Offerings to Broaden Hematology Testing Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to progress with test menu expansion.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.
Varian Medical's (VAR) Halcyon Gets NMPA Approval in China
by Zacks Equity Research
Varian Medical (VAR) enjoys significant international presence in radiotherapy.
Walgreens Gains from New Alliances, International Expansion
by Zacks Equity Research
Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.
Integra's (IART) Margin Pressure Hurts, Global Prospects High
by Zacks Equity Research
Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
Quest Diagnostics to Buy Laboratory Services Unit in Midwest
by Zacks Equity Research
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail
by Zacks Equity Research
The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.
Align Technology's New iTero Scanner Updates to Boost Uptake
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull
by Zacks Equity Research
Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.
Here's Why You Should Invest in Merit Medical (MMSI) Now
by Zacks Equity Research
A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.